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Background: Individuals with Burkholderia spp. infection have historically been excluded from efﬁcacy trials of inhaled antibiotics, including
aztreonam for inhalation solution (AZLI).
Methods: A double-blind, placebo-controlled, 24-week trial of continuous AZLI/placebo treatment was undertaken in individuals with cystic
ﬁbrosis (CF) and chronic Burkholderia spp. infection. All subjects also received usual medical care (determined by their physicians). Additional
antibiotic use was not restricted.
Results: Baseline FEV1% predicted values ranged from 15.8% to 114.6%. No signiﬁcant treatment differences (AZLI vs. placebo) were observed
at week 24 for any endpoints, including FEV1% predicted, number of respiratory exacerbations requiring systemic/inhaled antibiotics, or
hospitalizations. Continuous AZLI administration was well tolerated. Burkholderia spp. susceptibility to antibiotics commonly used in CF therapy
showed little change.
Conclusions: 24-weeks of continuous AZLI treatment did not signiﬁcantly improve lung function in CF subjects with chronic Burkholderia spp.
infection. Non-study antibiotic use may have confounded any potential AZLI effects.
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Cystic fibrosis (CF) is characterized by a robust inflammatory
response to chronic respiratory tract infection, leading to
progressive airway obstruction and loss of lung function.
Burkholderia gladioli and species in the Burkholderia cepacia
complex are amongst the many opportunistic bacterial pathogens
that cause respiratory infections in individuals with CF [1]. The
prevalence of B. cepacia complex infection in individuals with
CF is approximately 3% in North America; however, it varies
significantly between treatment centers [1–3]. Burkholderiaby Elsevier B.V. All rights reserved.
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mortality in individuals with CF, including more frequent and
difficult-to-treat exacerbations, weight loss, and accelerated lung
function loss [4,5]. Nevertheless, individuals with Burkholderia
infection have historically been excluded from efficacy trials of
inhaled antibiotics and currently there is no consensus regarding
treatment of Burkholderia infection in individuals with CF [5,6].
Aztreonam for inhalation solution (AZLI; Cayston®; Gilead
Sciences Inc.) is a monobactam antibiotic used to treat
individuals with CF and Pseudomonas aeruginosa infection.
During the AZLI Phase 3 clinical trials, anecdotal reports
emerged of positive responses by subjects with chronic
Burkholderia infection (Gilead Sciences, data on file). These
reports, together with the demonstrated in vitro activity of
AZLI against Burkholderia spp. [7–9], prompted consideration
of AZLI as a possible therapy for treating Burkholderia
infection. To this end, a double-blind, placebo-controlled,
24-week trial of continuous AZLI/placebo treatment was
undertaken in individuals with CF and chronic Burkholderia
infection [10–13]. Results from this prospective multicenter
trial also provided a unique opportunity to obtain a contempo-
rary picture of the clinical and microbiological characteristics
of individuals with CF and chronic Burkholderia infection.2. Methods
2.1. Study design
This Phase 3, double-blind, randomized, placebo-controlled,
2-part study was conducted at 35 sites (US: 34; Canada: 1;
Feb 2010–Sept 2011). After screening, eligible subjects were
stratified by region (due to differences in treatment-center
approaches); and randomly assigned (1:1) to 24 weeks of
continuous treatment with AZLI 75 mg or placebo, adminis-
tered 3 times daily (weeks 0–24; comparative period); followed
by a 24-week extension period of open-label AZLI treatment
for all subjects (weeks 24–48); and a 4-week follow-up period
(weeks 48–52). Subjects and investigators remained blinded to
randomized treatment-assignments during the extension/follow-up
periods. Subjects continued to receive their usual medical care,
determined by their physicians, with no restrictions on additional
antibiotic use.
Spirometry was performed according to American Thoracic
Society guidelines at each visit (every 4 weeks). Forced expiratory
volume in 1 s (FEV1)% predictedwas calculatedwith Hankinson's
(adult subjects) and Wang's (pediatric) equations [14,15]. A
medical reviewer, blinded to treatment-arm assignment, confirmed
hospitalizations for respiratory exacerbations and antibiotic use
during the study or in the 2 previous years.
AZLI (75 mg aztreonam, 52.5 mg lysine monohydrate) and
placebo (5 mg lactose, 7.3 mg NaCl), reconstituted in 0.17%
NaCl, were administered with the PARI Investigational eFlow®
Nebulizer System (PARI Respiratory Equipment; Midlothian,
VA, USA); ≥4 h separated the doses. AZLI/placebo was
administered in the clinic at the first visit of each period and
treatment-induced bronchospasm was monitored. Treatmentadherence was assessed by counting returned used/unused
AZLI/placebo vials.
The study was conducted in accordance with the principles of
the Declaration of Helsinki (as amended in Edinburgh, Tokyo,
Venice, Hong Kong, and South Africa), ICH guidelines, or with
the laws and regulations of the study countries, whichever
afforded the greater protection to the study subject. Institutional
review boards/independent ethics committees approved the study
for each site. Subjects (or parents, guardians, or legally authorized
representatives) provided written informed consent (assent) prior
to any study-related procedures.
2.2. Study population
Eligible subjects (≥6 years of age) had documented CF and
chronic infection with Burkholderia spp., defined at baseline
for subjects with sputum or bronchoalveolar lavage samples as:
1) a culture positive for Burkholderia spp. within 6 months
before baseline, 2) ≥50% of cultures (collected ≥1 month
apart) over the prior 12 months positive for Burkholderia spp.
(≥2 positive cultures), and 3)≥1 culture (obtained at any time)
confirmed to be a Burkholderia spp. by the CF Foundation
B. cepacia Research Laboratory and Repository (BcRLR;
University of Michigan, Ann Arbor, MI). For subjects with
only oropharyngeal culture results available for the previous
12 months, chronic infection with Burkholderia spp. was
confirmed by meeting the above criteria and: 1) ≥1 prior
lower respiratory tract culture(s) (expectorated, induced sputum,
or bronchoalveolar lavage, obtained at any time) positive for
Burkholderia spp., confirmed at the BcRLR, and 2) concordance
of the species isolated from prior lower respiratory tract culture(s)
and recent oropharyngeal cultures (prior 12 months).
Additional study methods and inclusion/exclusion criteria
are presented in an online appendix.
2.3. Study endpoints
The primary efficacy endpoint was mean relative change
from baseline FEV1% predicted, measured by AUCave (mean
area under the curve corrected for baseline and adjusted by
number of days on study) through week 24. Key secondary
endpoints included: number of respiratory exacerbations
requiring IV, oral, and/or inhaled antibiotics; number of
respiratory hospitalizations; AUCave through week 24 for CF
Questionnaire-Revised (CFQ-R [16]) Respiratory Symptoms
scores; and time to respiratory exacerbation requiring IV, oral,
and/or inhaled antibiotics. Expectorated sputum/oropharyngeal
swab samples were collected for microbiology assessments
(weeks 0, 4, 12, 24, 28, 36, 48, 52) [17,18]. Identification of
Burkholderia spp. and related species was performed as described
[19–23]. Adverse events were assessed throughout the study.
2.4. Statistical analyses
Analyses included subjects receiving ≥1 dose of AZLI/
placebo. Missing data were not imputed. A sample size of 50
subjects per treatment group was estimated as providing ≥80%
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AUCave of relative change from baseline in FEV1% predicted
through week 24 (2-sided, 0.05-level), assuming a common
standard deviation (SD) of 15. The primary analysis used a
parametric analysis of covariance (ANCOVA) model (2-sided,
0.05-level); baseline FEV1% predicted was a covariate. Analysis
methods for key secondary and other endpoints are described in
Table 2. A family alpha spending rule controlled the Type 1 error
rate (α = 0.05), with the primary endpoint analysis serving as
gatekeeper, and key secondary endpoints tested sequentially
(α = 0.05) based upon the closed testing procedure [24].
3. Results
3.1. Disposition
Of 102 screened subjects, 101 were randomized and 100
were treated with AZLI (n = 48) or placebo (n = 52) during the
comparative period. Overall, 84.0% of subjects (n = 84/100)
completed the comparative period and continued into the AZLITable 1
Subject demographics and baseline characteristics.
A
Age, years Mean (SD) 2
Min., max. 7
Age group ≥18 years; n (%) 4
N12 to b18 years; n (%) 3
≥6 to ≤12 years; n (%) 3
Gender Male; n (%) 2
BMI, kg/m2 Mean (SD) 2
CFTR genotype F508 del. homozygote; n (%) 2
F508 del. heterozygote; n (%) 9
Unidentified or other; n (%) 5
Missing; n (%) 7
CF-related diabetes; n (%) 1
FEV1% predicted Mean (SD) 6
Min., max. 1
CFQ-R RSS scores a Mean (SD) 5
Baseline non-study medications; n (%)
Azithromycin 3
Dornase alfa 3
Hypertonic saline 2
Any antibiotic; any route of administration 3
Any inhaled antibiotic 5
Subjects hospitalized in previous 2 years; n (%) 3
No. hospitalizations in previous 2 years 1
Subjects using antibiotics in previous 2 years; n (%) 4
No. courses in previous 2 years; mean (SD) 2
Positive culture for Burkholderia spp.; b n (%) 4
Highest aztreonam MIC for Burkholderia spp.
4–8 μg/mL 6
16–128 μg/mL 2
≥256 μg/mL 1
Subjects with Burkholderia spp. and CFU/g sputum data 2
Log10 CFU/g sputum; mean (SD) 6
Note: Characteristics were collected at screening or baseline (week 0; the beginning
BMI = body mass index; CFQ-R = Cystic Fibrosis Questionnaire-Revised; CFTR
forming units; Del. = deletion; FEV1 = forced expiratory volume in 1 s; Max
RSS = Respiratory Symptoms domain scores; SD = standard deviation.
a CRQ-R RSS scores available for 98 subjects (AZLI: 46; placebo: 52).
b Data available for 46 (AZLI), 50 (placebo), and 96 (total) subjects.extension period, and 90.0% of these subjects (n = 76/84)
completed the extension period (Online Fig. 1). Seven subjects
(all treated with AZLI during comparative (n = 5) or extension
(n = 2) periods) discontinued from the study due to an adverse
event(s); most were respiratory events. The majority of subjects
took ≥80% of expected AZLI/placebo doses during the
comparative and extension periods.
3.2. Demographics and baseline characteristics
Demographic and baseline characteristics were well balanced
between treatment arms, except that mean (SD) baseline FEV1%
predicted was higher in the AZLI arm (60.7 [21.7]) than that in the
placebo arm (52.6 [23.7]; Table 1). Overall, baseline FEV1%
predicted values ranged from 15.8% to 114.6%. Most subjects
were ≥18 years old (83.0%; n = 83/100). Most subjects had
a positive culture for Burkholderia spp. at baseline (94.8%;
n = 91/96), although the proportion able to provide a sputum
sample of sufficient quantity for Burkholderia spp. sputum
density analysis was much lower (61.5%; n = 59/96).ZLI (n = 48) Placebo (n = 52) Total (n = 100)
8.0 (10.3) 24.7 (10.0) 26.3 (10.2)
.0, 53.0 6.0, 57.0 6.0, 57.0
2 (87.5) 41 (78.8) 83 (83.0)
(6.3) 8 (15.4) 11 (11.0)
(6.3) 3 (5.8) 6 (6.0)
6 (54.2) 35 (67.3) 61 (61.0)
1.9 (4.5) 20.7 (3.2) 21.3 (3.9)
7 (56.3) 26 (50.0) 53 (53.0)
(18.8) 10 (19.2) 19 (19.0)
(10.4) 6 (11.5) 11 (11.0)
(14.6) 10 (19.2) 17 (17.0)
5 (31.3) 19 (36.5) 34 (34.0)
0.7 (21.7) 52.6 (23.7) 56.5 (23.0)
7.0, 108.5 15.8, 114.6 15.8, 114.6
8.3 (21.4) 59.0 (17.6) 58.6 (19.4)
0 (62.5) 31 (59.6) 61 (61.0)
6 (75.0) 37 (71.2) 73 (73.0)
4 (50.0) 21 (40.4) 45 (45.0)
9 (81.3) 41 (78.8) 80 (80.0)
(10.4) 12 (23.1) 17 (17.0)
6 (75.0) 44 (84.6) 80 (80.0)
21 187 308
8 (100.0) 50 (96.2) 98 (98.0)
2.8 (15.5) 26.0 (18.5) 24.5 (17.1)
4 (95.7) 47 (94.0) 91 (94.8)
8 14
0 17 37
8 22 40
8 29 57
.85 (1.82) 7.07 (1.47) 6.96 (1.64)
of the comparative period).
= cystic fibrosis transmembrane conductance regulator gene; CFU = colony
. = maximum; MIC = minimum inhibitory concentration; Min. = minimum;
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demonstrated high minimum inhibitory concentrations (MICs)
for aztreonam. The MICs at which 50% and 90% of isolates
were inhibited (MIC50 and MIC90) for aztreonam were 64 and
512 μg/mL, for the AZLI arm respectively, and 128 and
1024 μg/mL, for the placebo arm respectively. At week 24, theTable 2
Selected efficacy data for the comparative period (weeks 0 to 24).
AZLI (n = 48) Placeb
Adj. mean (SE) for AUCave of relative change from baseline at week 24 for:
FEV1% predicted
a 0.16 (1.50) −0.
CFQ-R RSS score c 2.97 (1.70) 2.7
Adj. mean (SE) for actual change from baseline at week 24 for:
BMI d kg/m2 0.34 (0.16) 0.2
Log10 Burkholderia spp. CFU/g sputum
f 1.41 (0.58) 0.4
Other efficacy comparisons AZLI
Subjects with IV, oral, and/or inhaled antibiotic use for
any respiratory indication; g, h n (%)
39
Subjects with IV, oral, and/or inhaled antibiotic use for
respiratory exacerbation; h, i n (%)
29
Time to antibiotic use for respiratory exacerbation; i, j, k
estimated median days (95% CI)
75.0 (
Number of unique days of IV, oral, and/or inhaled
antibiotic use for any respiratory indication; g, l mean (SD)
70
Cumulative days of IV, oral, and/or inhaled antibiotic
use for any respiratory indication (antibiotic burden) l, m
111
Number of unique days of IV, oral, and/or inhaled
antibiotic use for respiratory exacerbations; a, i, l mean (SD)
26
Total number of IV, oral, and/or inhaled antibiotic
courses for respiratory exacerbation i, n
IV, oral, and/or inhaled antibiotic course rate per subject
year for respiratory exacerbation i
Subjects hospitalized at least once for respiratory
exacerbation; h, i n (%)
17
Number of days hospitalized for respiratory
exacerabations; i mean (SD)
15
Total number of respiratory hospitalizationsi. n
Respiratory hospitalization rate per subject-year i
Percent of days of missed school/work; l, o mean (SD) 1
Adj. = adjusted; AUCave = calculated area under the curve corrected for baseline and ad
Fibrosis Questionnaire-Revised; CI = confidence interval; CFU = colony forming unit
Symptoms Scale scores; SD = standard deviation; SE = standard error.
a n = 47 (AZLI), 52 (placebo).
b p-Value for treatment difference was based on an analysis of covariance (ANCO
c n = 45 (AZLI), 52 (placebo).
d n = 39 (AZLI), 45 (placebo).
e p-Value was based on a mixed-effect model repeated measure (MMRM) model th
f n = 15 (AZLI), 20 (placebo).
g Includes maintenance therapies for chronic lung infection and treatments for respi
3 antibiotics on 1 day counted as 1 unique day of antibiotic use).
h Compared with Fisher's exact test.
i Antibiotics used for respiratory exacerbations and hospitalizations for respiratory ex
started on or after the ﬁrst dose date were included. A single antibiotic course may rep
j Median estimated with Kaplan–Meier methods.
k p-Value was based on log-rank test.
l Compared with Wilcoxon rank sum test.
m Includes maintenance therapies for chronic lung infection and treatments for res
and all days (e.g., receiving 3 antibiotics on 1 day counted as 3 days of antibiotic u
n Compared with a negative binomial regression model.
o n = 32 (AZLI), 40 (placebo).baseline for subjects entering the extension period, characteristics
did not differ substantially from those of week 0, although the
difference between treatment groups in FEV1% predicted values
had increased. The mean (SD) FEV1% predicted was 62.2 (20.9)
for subjects receiving AZLI during both the comparative and
extension periods (AZLI/AZLI) and was 50.4 (24.5) for subjectso (n = 52) p-Value Treatment difference (95% CI)
75 (1.43) 0.663 b 0.91 (−3.24, 5.06)
9 (1.58) 0.939 b 0.18 (−4.43, 4.78)
1 (0.15) 0.531 e 0.14 (−0.29, 0.56)
8 (0.50) 0.232 b 0.93 (−0.62, 2.48)
(n = 48) Placebo (n = 52) p-Value
(81.3) 49 (94.2) 0.06
(60.4) 38 (73.1) 0.206
49.0, 117.0) 51.0 (35.0, 95.0) 0.266
.3 (59.5) 91.7 (60.7) 0.071
.3 (101.2) 148.4 (117.2) 0.105
.1 (31.3) 38.2 (38.3) 0.094
54 73 0.416
2.69 3.13 NA
(35.4) 21 (40.4) 0.682
.3 (11.4) 20.4 (24.8) NA
25 32 0.807
1.24 1.37 NA
.9 (3.3) 4.7 (7.6) 0.284
justed by the number of days on study; BMI = bodymass index; CFQ-R = Cystic
s; FEV1 = forced expiratory volume in 1 s; IV = intravenous; RSS = Respiratory
VA) model with baseline value as a covariate.
at included terms for treatment, visit, baseline, and treatment × visit interaction.
ratory exacerbations; days of antibiotic use included unique days (e.g., receiving
acerbations were determined by a blinded medical reviewer. Only antibiotics that
resent the use of multiple antibiotics. Days of antibiotic use included unique days.
piratory exacerbations; cumulative days of antibiotic use included all antibiotics
se).
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during the extension period (placebo/AZLI).
3.3. Efficacy
The primary efficacy endpoint, adjusted mean (SE) AUCave
of relative change from baseline in FEV1% predicted at week
24, was not significantly different for subjects treated with
AZLI (0.16 [1.50]) or placebo (−0.75 [1.43]), with a treatment
difference of 0.91 (95% confidence interval [CI]: −3.24, 5.06;
p = 0.66; Table 2). When subgroups were examined, AUCave
was numerically higher for AZLI-treated subjects than for
placebo-treated subjects for some subgroups, but no statistically
significant (p ≤ 0.05) treatment differences were observed
(Online Fig. 2). Adjusted mean (SE) AUCave of relative change
from baseline CFQ-R Respiratory Symptom scores at week 24
were also similar for the AZLI- and placebo-treated subjects
(p = 0.939; Table 2). Numerical improvements after AZLI
treatment were observed for some secondary efficacy end-
points, including incidences of respiratory exacerbations and
hospitalizations; however, AZLI vs. placebo treatment differ-
ences were not statistically significant.
A majority of subjects received IV, oral, or inhaled
antibiotics other than AZLI for respiratory exacerbations during
the comparative (AZLI: 60.4%; placebo: 73.1%) and extension
(AZLI/AZLI: 79.5%; placebo/AZLI: 75.6%) study periods
(Table 2; Online Table 1). The incidence of non-AZLI
antibiotic use during the comparative period was greater when
antibiotics prescribed for all respiratory indications (i.e.,
maintenance therapy and/or acute exacerbation treatments)
were included (AZLI: 81.3%; placebo: 94.2%). In exploratory
analyses, no significant AZLI vs. placebo treatment differences
were observed in the primary efficacy endpoint, after adjusting
for number of courses of IV/oral/inhaled antibiotics used for
respiratory exacerbations during the comparative period. In
similar analyses, no differences were found when adjusting for
either number of unique days on additional antibiotics or total
antibiotic-days (antibiotic burden). The largest improvements
in relative change in FEV1% predicted occurred after the firstTable 3
Isolation of individual Burkholderia species.
Burkholderia species Isolation during comparative period (wee
AZLI (n = 48)
n (%)
Placebo
n (%)
B. cenocepacia 20 (41.7) 22 (42.3
B multivorans 17 (35.4) 16 (30.8
B. gladioli 3 (6.3) 5 (9.6)
B. dolosa 3 (6.3) 3 (5.8)
B. vietnamiensis 2 (4.2) 1 (1.9)
Burkholderia spp. (indeterminate) 1 (2.1) 2 (3.8)
B. ambifaria 1 (2.1) 1 (1.9)
B. metallica 1 (2.1) 0 (0)
B. cepacia 0 (0) 1 (1.9)
Burkholderia spp. absent 0 (0) 1 (1.9)
a Data available for 96 of 100 subjects.28-days of AZLI treatment during the comparative period
(AZLI group) or the extension period (placebo/AZLI group;
Online Fig. 3).3.4. Safety
During the 24 week comparative period, the incidence of the
most commonly observed adverse events was generally compa-
rable between treatment arms, although wheezing (AZLI: 20.8%;
placebo: 5.8%) and chills (AZLI: 12.5%; placebo: 3.8%) were
reported for more AZLI-treated than placebo-treated subjects
when considered by incidence (Online Table 2) or after adjusting
for study duration (Online Table 3). The wheezing observed
among AZLI-treated subjects appeared to be associated with
underlying disease (asthma or prior history of wheezing), was
associated with a viral infection, or was one of multiple
symptoms reported for acute pulmonary exacerbation. The onsets
of the events of wheezing were distributed across the comparative
period and most events resolved on study. One subject
discontinued from the study due to wheezing and several other
respiratory events; the subject also experienced a concomitant
exacerbation of CF. The chills observed among AZLI-treated
subjects were one of multiple symptoms reported for a viral
infection or a pulmonary exacerbation. The onsets of the events
of chills were distributed across the comparative period and all
events resolved on study. Eleven AZLI-treated (22.9%) and 10
placebo-treated (19.2%) subjects experienced severe adverse
events; the majority was respiratory events and all were
considered by the investigators as unrelated to treatment. One
life-threatening adverse event (respiratory failure) and 2 deaths
(progressive CF lung disease [baseline FEV1% predicted: 16.95];
and acute hypercarbic respiratory failure [baseline FEV1%
predicted: 21.08]) were reported during the comparative period;
all occurred in the AZLI-treatment group and were considered
unrelated to treatment. Treatment-related adverse events were
reported for 9 AZLI-treated (18.8%) and 3 placebo-treated
(5.8%) subjects, with respiratory events reported for all 9
AZLI-treated and none of the placebo-treated subjects.ks 0 to 24) MIC range for aztreonam at baseline (all isolates)
(n = 52) MIC range
(μg/mL)
No.
subjects a
No.
isolates
) 8 to N2048 40 73
) 2 to N2048 27 49
16 to 128 8 14
4 to 1024 6 10
2 to 64 3 6
4 to 1024 3 6
32 to 2048 2 6
32 1 2
1024 1 1
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incidences were generally comparable to those observed during
the comparative period (Online Table 2; Online Table 3). Two
deaths were reported: respiratory failure related to CF lung
disease (AZLI/AZLI; baseline FEV1% predicted: 31.25) and
sepsis (placebo/AZLI; baseline FEV1% predicted: 62.48); both
were considered unrelated to treatment.
Airway reactivity (≥15% drop in FEV1 [L] 30 min after
administering study medication) was not reported for any
subjects at either the comparative or extension period baseline
visits.
3.5. Microbiology
B. cenocepacia and B multivorans were the most commonly
observed Burkholderia spp. and a range of MIC values for
aztreonam were observed at baseline amongst the isolates of
each species (Table 3). As expected for a chronic infection in
individuals with CF, positive cultures for Burkholderia spp.
were observed for N90% of subjects at each assessment during
the comparative period; only 1 subject never tested positive for
Burkholderia spp. (placebo group). Positive sputum cultures
were also observed for P. aeruginosa (44.8% subjects; n = 43/96)
and methicillin-resistant Staphylococcus aureus (MRSA; 38.6%
subjects; n = 37/96; Table 4). Appearance of other respiratory
pathogens during the comparative period was comparable between
the AZLI and placebo treatment groups (Table 4).
Burkholderia spp. and P. aeruginosa susceptibility to
antibiotics commonly used in CF therapy was examined across
the study (Fig. 1). A 4-fold increase from baseline for the
aztreonam MIC50 for Burkholderia spp. was observed in the
AZLI, but not the placebo arm, at the end of the comparative
period (week 24). At week 24, other changes from baseline
MIC50 differed 2-fold or less between treatment arms. It was
only possible to compare change in bacterial density (log10
colony forming units [CFU]/g sputum) for subjects with data at
both baseline and week 24; this analysis included subjects who
expectorated adequate sputum samples and/or subjects with
smaller sputum samples or throat swabs who were confirmed
negative for Burkholderia spp. at one or both time points.
Adjusted mean (SE) change in Burkholderia spp. density
from baseline to week 24 was 1.41 (0.58) for AZLI-treated
(n = 15/39) and 0.48 (0.50) for placebo-treated (n = 20/46)
subjects (p = 0.232). Adjusted mean (SE) change inP. aeruginosa
density from baseline to week 24 was 0.00 (0.64) for AZLI-treated
(n = 9/39) and 0.93 (0.58) for placebo-treated (n = 11/46) subjects
(p = 0.307).
4. Discussion
This study was the largest, randomized, placebo-controlled
trial to evaluate the safety and efficacy of inhaled antibiotic
therapy in individuals with CF and Burkholderia infection.
Although these infections are associated with significant
morbidity and mortality, a recent Cochrane Review identified
no published randomized or quasi-randomized controlled trials
of treatments for exacerbations of pulmonary symptoms in
Fig. 1. MIC50 values of selected antibiotics for Burkholderia spp. and P. aeruginosa. Burkholderia spp. (BURK) isolates were obtained from 44, 41, 40, and 35
AZLI-treated subjects and 47, 47, 42, and 40 placebo-treated subjects at weeks 0, 4, 12, and 24, respectively and from 35, 34, 33, 33, and 31 AZLI/AZLI-treated
subjects and 39, 39, 36, 38, and 33 AZLI/placebo-treated subjects at weeks 24, 28, 36, 48, and 52, respectively. The number of isolates tested at any time point for any
group ranged from 58 to 102. P. aeruginosa (PA) isolates were obtained from 16, 13, 18, and 10 AZLI-treated subjects and 13, 15, 11, and 12 placebo-treated subjects
at weeks 0, 4, 12, and 24, respectively, and from 10, 11, 13, 11, and 13 AZLI/AZLI-treated subjects and 12, 8, 9, 6, and 9 AZLI/placebo-treated subjects at weeks 24,
28, 36, 48, and 52, respectively. The number of isolates tested at any time point for any group ranged from 14 to 37. MIC50 = minimum inhibitory concentration at
which 50% of isolates are inhibited.
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[6]. The vast majority of published clinical data on Burkholderia
infection in individuals with CF is comprised of uncontrolled,
anecdotal, and/or single center experiences, and no consensus has
emerged regarding treatment [5,6].The Burkholderia spp. observed in this study are consistent
with previous reports, with B. cenocepacia and B. multivorans
as the most common species identified [26]. There were no
enrollment restrictions on FEV1% predicted and baseline lung
function varied widely in the study population. FEV1% predicted
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neity amongst subjects in both severity of the CF phenotype [27]
and lung disease stage.
In this study of chronic Burkholderia-infected individuals
with CF who were receiving usual medical treatment, we
observed no significant treatment difference between AZLI-
and placebo-treated groups in FEV1% predicted over the
6-month comparative treatment period. Similarly, no differ-
ences were observed between treatment groups with respect to
acute respiratory exacerbations, hospitalizations for respira-
tory exacerbations, and additional antibiotic use either for
respiratory exacerbations or for all respiratory indications.
The largest increases in FEV1% predicted occurred during the
first 28 days of AZLI treatment, but such increases were not
sustained across the subsequent months of continuous
treatment. Exploratory analyses did not identify subgroups
that showed a statistically significant differential treatment
response to AZLI, including subgroups based on gender, age,
baseline lung function, specific Burkholderia spp., antibiotic
use, baseline aztreonam MIC for infecting organisms, or
co-infection with P. aeruginosa or MRSA. It is not possible to
determine whether these results are due to lack of treatment
effect or to small numbers in these subgroups leading to
underpowered analyses.
In contrast to other efficacy trials of inhaled antibiotics in CF,
this trial allowed use of systemic or other inhaled antibiotics for
maintenance treatment of chronic respiratory infections and study
subjects had substantial additional antibiotic exposure. In fact,
higher percentages of subjects received antibiotics for acute
respiratory exacerbations during the comparative period of this
trial (AZLI: 60.4%, placebo: 73.1%) than in a recent AZLI vs.
tobramycin inhalation solution (TIS) comparative trial for subjects
with CF and P. aeruginosa infection (AZLI: 38.2%, TIS: 57.6%)
[28]. Further, the incidence of antibiotic use for any respiratory
indication in the comparative period of the current trial was even
higher (AZLI: 81.3% of subjects, placebo: 94.2%). This lack of
restrictions on ongoing or newly initiated antibiotic therapy
presented a limitation to this study. It is possible that extensive
antibiotic exposure had confounding effects on the efficacy results
in this study, limiting the potential for incremental responses to
AZLI treatment. Nevertheless, we believed this design was
necessary given a priori concerns that CF care providers have
regarding the risk of poor outcomes for individuals infected with
Burkholderia spp.
There was no significant decrease in either Burkholderia spp.
or P. aeruginosa sputum density when comparing AZLI and
placebo treatment groups. This differs markedly from a previous
AZLI Phase 3 trial, in which mean P. aeruginosa sputum density
decreased 1.453 log10 CFU/g [25]. It is unclear what caused
the lack of decrease in sputum density in the current study.
Sputum density measurements may have been impacted by
additional antibiotic use or by the number of subjects who could
produce samples of sufficient quantity for bacterial density
analysis; this changed from 63.0% (n = 29/46) to 51.4%
(n = 19/37) of AZLI-treated and from 60.00% (n = 30/50) to
61.4% (n = 27/44) of placebo-treated subjects from baseline to
the end of the comparative period.It is difficult to draw on experience from the AZLI trials in
CF patients with chronic P. aeruginosa infection because there
are 2 variables in the current study that differ from previous
studies: the presence of Burkholderia spp., an inherently more
antibiotic-resistant organism, and a different treatment regimen,
a continuous therapy instead of intermittent 28-day on/off
treatment periods. Both of these factors would be expected
to have influences on the complex microbiome of these CF
patients with Burkholderia infection. The exact nature of these
effects as well as the corresponding clinical outcomes is open to
speculation and in need of further scientific study.
In this study we chose to use continuous, rather than
intermittent administration of inhaled AZLI. This was based on
consideration of: 1) high airway concentrations achieved by
AZLI and lack of emergent resistance observed during
18 months of intermittent use for P. aeruginosa infection in
subjects with CF [29], and 2) treatment benefits and current
treatment practices: subjects receiving intermittent AZLI
therapy for 18 months experienced recrudescence of symptoms
during off-treatment periods [29], and individuals with CF and
Burkholderia infections often receive continuous antibiotics as
part of clinical care. We observed that continuous AZLI therapy
for up to 48 weeks did not increase the prevalence of other
respiratory pathogens, nor did it compromise P. aeruginosa
susceptibility to AZLI or other commonly used antipseudomonal
antibiotics. Continuous AZLI therapy was also well tolerated. No
new safety signals were detected and the adverse event profile
was consistent with previous AZLI clinical trial experience
[25,28–31]. Four of the 100 subjects died during this 1 year
study. Three deaths were caused by respiratory failure/advanced
CF disease and the fourth by sepsis. This mortality rate was
numerically higher than that observed in the general CF
population (1.5 deaths were reported per 100 individuals in the
2010 CFF Registry database of 26,298 individuals [32]), and
likely reflects the increased mortality in the population of
individuals with CF and Burkholderia infection.
This study demonstrated that it was feasible to enroll a 100
patient study relatively quickly. Given the heterogeneity of the
study population, subsequent studies could utilize narrower
inclusion criteria in order to select a more homogenous study
population and increase the chance of measuring a treatment
benefit. Examples could include excluding patients with
FEV1 N 75% predicted or including only those with a history
of frequent pulmonary exacerbations. However, stricter
inclusion criteria will limit the availability of qualifying
patients and could create challenges to enrolling an adequately
powered study.
In conclusion, although 24-week continuous AZLI treatment
did not demonstrate a significant improvement in lung function,
this study has created a unique and comprehensive clinical and
microbiological dataset describing individuals with CF and
chronic Burkholderia infection. Further, individuals with CF
and Burkholderia infection were willing and able to participate
in this study without adverse consequences, which suggest that
future trials could be conducted in this patient population. The
results of the current trial will be informative in the design of
such future studies.
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